疾病活动标准对新生血管性年龄相关性黄斑变性试验中的给药间隔分配产生影响。 - Suppr

Disease Activity Criteria Impact Dosing Interval Assignment in Neovascular Age-related Macular Degeneration Trials.

作者信息

Zarbin Marco A, Weng Christina Y, London Nikolas J S, Koh Adrian Hock Chuan, Gallego-Pinazo Roberto, Chaudhary Varun, Souverain Audrey, Stoilov Ivaylo, Margaron Philippe

机构信息

Rutgers New Jersey Medical School, Newark, New Jersey.

Baylor College of Medicine, Cullen Eye Institute, Houston, Texas.

出版信息

Ophthalmol Retina. 2025 Apr;9(4):404-407. doi: 10.1016/j.oret.2024.12.021. Epub 2024 Dec 27.

DOI:10.1016/j.oret.2024.12.021

PMID:39733838

Abstract

摘要

相似文献

Disease Activity Criteria Impact Dosing Interval Assignment in Neovascular Age-related Macular Degeneration Trials.

Ophthalmol Retina. 2025 Apr;9(4):404-407. doi: 10.1016/j.oret.2024.12.021. Epub 2024 Dec 27.

TENAYA and LUCERNE: Rationale and Design for the Phase 3 Clinical Trials of Faricimab for Neovascular Age-Related Macular Degeneration.

Ophthalmol Sci. 2021 Nov 17;1(4):100076. doi: 10.1016/j.xops.2021.100076. eCollection 2021 Dec.

Efficacy, Durability and Safety of Faricimab in Neovascular Age-Related Macular Degeneration and Diabetic Macular Oedema: Lessons Learned from Registration Trials.

Ophthalmol Ther. 2023 Oct;12(5):2253-2264. doi: 10.1007/s40123-023-00753-6. Epub 2023 Jul 6.

TENAYA and LUCERNE: Two-Year Results from the Phase 3 Neovascular Age-Related Macular Degeneration Trials of Faricimab with Treat-and-Extend Dosing in Year 2.

Ophthalmology. 2024 Aug;131(8):914-926. doi: 10.1016/j.ophtha.2024.02.014. Epub 2024 Feb 19.

Efficacy of Every Four Monthly and Quarterly Dosing of Faricimab vs Ranibizumab in Neovascular Age-Related Macular Degeneration: The STAIRWAY Phase 2 Randomized Clinical Trial.

JAMA Ophthalmol. 2020 Sep 1;138(9):964-972. doi: 10.1001/jamaophthalmol.2020.2699.

Efficacy, durability, and safety of faricimab up to every 16 weeks in patients with neovascular age-related macular degeneration: 1-year results from the Japan subgroup of the phase 3 TENAYA trial.

Jpn J Ophthalmol. 2023 May;67(3):301-310. doi: 10.1007/s10384-023-00985-w. Epub 2023 Apr 11.

Efficacy, durability and safety of faricimab for patients with neovascular age-related macular degeneration: 48-week results from the phase 3 LUCERNE China subpopulation.

Asia Pac J Ophthalmol (Phila). 2025 Jan-Feb;14(1):100142. doi: 10.1016/j.apjo.2025.100142. Epub 2025 Jan 14.

Intravitreal faricimab for neovascular age-related macular degeneration previously treated with traditional anti-VEGF compounds: a real-world prospective study.

Graefes Arch Clin Exp Ophthalmol. 2024 Apr;262(4):1151-1159. doi: 10.1007/s00417-023-06319-3. Epub 2023 Dec 4.

Efficacy, durability, and safety of faricimab in patients from Asian countries with neovascular age-related macular degeneration: 1-Year subgroup analysis of the TENAYA and LUCERNE trials.

Graefes Arch Clin Exp Ophthalmol. 2023 Nov;261(11):3125-3137. doi: 10.1007/s00417-023-06071-8. Epub 2023 Jun 9.

Anatomic Outcomes with Faricimab vs Aflibercept in Head-to-Head Dosing Phase of the TENAYA/LUCERNE Trials in Neovascular Age-related Macular Degeneration.

Ophthalmology. 2025 May;132(5):519-526. doi: 10.1016/j.ophtha.2024.11.023. Epub 2024 Nov 30.

引用本文的文献

Faricimab in the Treatment of Exudative Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema in Italy: The FARIT Real World Study.

Ophthalmol Ther. 2025 Jul 19. doi: 10.1007/s40123-025-01204-0.

Automated and code-free development of a risk calculator using ChatGPT-4 for predicting diabetic retinopathy and macular edema without retinal imaging.

Int J Retina Vitreous. 2025 Jan 31;11(1):11. doi: 10.1186/s40942-025-00638-9.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Disease Activity Criteria Impact Dosing Interval Assignment in Neovascular Age-related Macular Degeneration Trials.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献